Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01750138
Other study ID # SNE1725
Secondary ID
Status Recruiting
Phase N/A
First received December 11, 2012
Last updated December 12, 2012
Start date June 2011

Study information

Verified date December 2012
Source Scarborough General Hospital
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The gastrointestinal tract has many functionsÍž it provides nutrition, produces hormones, performs a barrier function, maintains a stable gastrointestinal micro flora and plays an important role in the inflammatory process as it is the largest producer of cytokines (proteins associated with inflammation). This gut function is impaired after colorectal (bowel) surgery. There is evidence to suggest that impaired gut function is associated with increased complications. Hence if gut function is preserved, it should equate with better outcomes. As a result, there has been increasing interest in treatments called Gut Specific Nutrients (GSN), which specifically target gut function. Most notable of them is Glutamine, a conditionally essential amino acid and preferred fuel source for intestinal cells. Research has shown that glutamine promotes cell growth, increases clearance of harmful organisms from the blood, and reduces the surgical stress response. In other words, glutamine has a favourable influence on gut function.

Recent studies from our unit using intravenous glutamine in critically ill patients have shown an early return of gut function, which in turn is associated with attenuation of the inflammatory response and improved outcomes. It is not known whether oral glutamine is associated with a similar outcome. A recent pilot study at our unit suggests an association between oral glutamine and early return of gut function. The aim of this research is to determine if giving oral glutamine results in an early return of gut function and whether this is associated with an attenuation of the systemic inflammatory response.


Recruitment information / eligibility

Status Recruiting
Enrollment 206
Est. completion date
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 19 Years and older
Eligibility Inclusion Criteria:

- All adult patients undergoing elective colorectal surgery (both open or keyhole) will be eligible for the study.

Exclusion Criteria:

- Allergy to glutamine/placebo

- Failure to obtain informed consent.

- Patients with existing infections.

- Pregnant women and children under the age of 18 years will be excluded from the study.

- Patients on antibiotics in the previous 2 weeks.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)


Related Conditions & MeSH terms


Intervention

Drug:
Glutamine

Dextrose powder


Locations

Country Name City State
United Kingdom Scarborough District Hospital Scarborough North Yorkshire

Sponsors (1)

Lead Sponsor Collaborator
Scarborough General Hospital

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gut function post op No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06444139 - Probiotic Intervention for Occasional Constipation N/A
Recruiting NCT05155449 - Probiotic Intervention for Gut Function N/A